Oilatum Plus Bath Additive.Light liquid paraffin 52.5% w/wBenzalkonium chloride 6.0% w/wTriclosan 2.0% w/w

Χώρα: Ιρλανδία

Γλώσσα: Αγγλικά

Πηγή: HPRA (Health Products Regulatory Authority)

Δραστική ουσία:

Benzalkonium chloride; Triclosan; Light liquid paraffin

Διαθέσιμο από:

GlaxoSmithKline Consumer Healthcare (Ireland) Limited

Φαρμακολογική κατηγορία (ATC):

D08AJ; D08AJ01

INN (Διεθνής Όνομα):

Benzalkonium chloride; Triclosan; Light liquid paraffin

Δοσολογία:

52.5/6/2 percent weight/weight

Φαρμακοτεχνική μορφή:

Bath additive

Τρόπος διάθεσης:

Product not subject to medical prescription

Θεραπευτική περιοχή:

Quaternary ammonium compounds; benzalkonium

Καθεστώς αδειοδότησης:

Marketed

Ημερομηνία της άδειας:

1989-05-25

Αρχείο Π.Χ.Π.

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Oilatum Plus Bath Additive.
Light liquid paraffin 52.5% w/w
Benzalkonium chloride 6.0% w/w
Triclosan 2.0% w/w
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Bath additive.
A clear, pale yellow oily solution.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the treatment of infected eczemas and eczemas at risk from
infection.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Oilatum Plus should always be diluted with water. It is an effective
cleanser and should not be used with soap.
Bath: In an eight inch bath add 2 capfuls; in a four inch bath add 1
capful.
Infant bath: Add 1 ml (just sufficient to cover the bottom of the cap)
and mix well with water.
Soak for 15 minutes, gently pat the skin dry with a clean towel. Use
once daily.
4.3 CONTRAINDICATIONS
Patients with known hypersensitivity to any of the ingredients should
not use the product.
Not recommended for babies younger than 6 months.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Avoid contact of the undiluted product with the eyes.
Take care to avoid slipping in the bath.
Light liquid paraffin
52.5
% w/w
Benzalkonium chloride
6.0
% w/w
Triclosan
2.0
% w/w
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_1_
_/_
_1_
_1_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_2_
_1_
_8_
_4_
_6_
_7_
_5_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER F